title: MILES stage 1 data N1_1260


title: MILES stage 1 data N1_1262

status: Public on Sep 30 2009

type: RNA

city: Pleasanton

first: Wei-Min

last: Liu

state: CA

address: 4300 Hacienda Drive

country: USA

institute: Roche Molecular Systems

hyb_protocol: Hybridization, washing, and staining protocols, respectively, were performed on Affymetrix GeneChip instruments (Hybridization Oven 640, Fluidics Station FS450) as recommended by the manufacturer.

scan_protocol: Scanning was performed on Affymetrix GeneChip Scanner GCS3000 instruments as recommended by the manufacturer using default settings. The software used was GCOS 1.2 or higher.

data_processing: Data pre-processing included a summarization and quantile normalization step to generate probe set level signal intensities for each microarray experiment and was performed as previously published by Liu WM et al. PQN and DQN: algorithms for expression microarrays. J.Theor.Biol. 2006;243:273-278.

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: Leukemia patient sample

label_protocol: For each sample preparation, total RNA was converted into double-stranded cDNA by reverse transcription using a cDNA Synthesis System kit including an oligo(dT)24 – T7 primer (Roche Applied Science, Mannheim, Germany) and Poly-A control transcripts (Affymetrix, Santa Clara, CA, USA). The generated cRNA was purified using the GeneChip Sample Cleanup Module (Affymetrix) and quantified using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). The incubation steps during the cDNA synthesis, in vitro transcription reaction, and target fragmentation were performed using the Hybex Microarray Incubation System (SciGene, Sunnyvale, CA, USA) and Eppendorf ThermoStat plus instruments (Eppendorf, Hamburg, Germany).

growth_protocol: not applicable

extract_protocol: The total RNA was purified either with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) or with TRIzol-based protocols

treatment_protocol: Samples are from untreated patients.

tag: sample type

value: bone marrow

tag: leukemia class

value: AML complex aberrant karyotype


title: MILES stage 1 data N1_1253

value: AML with normal karyotype + other abnormalities


title: MILES stage 1 data N1_1256


title: MILES stage 1 data N1_1276


title: MILES stage 1 data N1_1266


title: MILES stage 1 data N1_1279


title: MILES stage 1 data N1_1272


title: MILES stage 1 data N1_1286


title: MILES stage 1 data N1_1258


title: MILES stage 1 data N1_1269


title: MILES stage 1 data N1_1255


title: MILES stage 1 data N1_1265


title: MILES stage 1 data N1_1254


title: MILES stage 1 data N1_1264


title: MILES stage 1 data N1_1257


title: MILES stage 1 data N1_1274


title: MILES stage 1 data N1_1275


title: MILES stage 1 data N1_1273


title: MILES stage 1 data N1_1263


title: MILES stage 1 data N1_1252


title: MILES stage 1 data N1_1246


title: MILES stage 1 data N1_1270


title: MILES stage 1 data N1_1248


title: MILES stage 1 data N1_1251


title: MILES stage 1 data N1_1247


title: MILES stage 1 data N1_1239

value: peripheral blood


title: MILES stage 1 data N1_1241


title: MILES stage 1 data N1_1249


title: MILES stage 1 data N1_1236


title: MILES stage 1 data N1_1245


title: MILES stage 1 data N1_1250


title: MILES stage 1 data N1_1235


title: MILES stage 1 data N1_1238


title: MILES stage 1 data N1_1243


title: MILES stage 1 data N1_1237


title: MILES stage 1 data N1_1231


title: MILES stage 1 data N1_1234


title: MILES stage 1 data N1_1230


title: MILES stage 1 data N1_1232


title: MILES stage 1 data N1_1225


title: MILES stage 1 data N1_1229


title: MILES stage 1 data N1_1242


title: MILES stage 1 data N1_1227


title: MILES stage 1 data N1_1240


title: MILES stage 1 data N1_1226


title: MILES stage 1 data N1_1228


title: MILES stage 1 data N1_1244


title: MILES stage 1 data N1_1233


title: MILES stage 1 data N1_1224


title: MILES stage 1 data N1_1223


title: MILES stage 1 data N1_1222


title: MILES stage 1 data N1_1221


title: MILES stage 1 data N1_1218


title: MILES stage 1 data N1_1215


title: MILES stage 1 data N1_1205


title: MILES stage 1 data N1_1211


title: MILES stage 1 data N1_1216


title: MILES stage 1 data N1_1212


title: MILES stage 1 data N1_1219


title: MILES stage 1 data N1_1207


title: MILES stage 1 data N1_1213


title: MILES stage 1 data N1_1217


title: MILES stage 1 data N1_1209


title: MILES stage 1 data N1_1214


title: MILES stage 1 data N1_1202


title: MILES stage 1 data N1_1203


title: MILES stage 1 data N1_1199


title: MILES stage 1 data N1_1200


title: MILES stage 1 data N1_1198


title: MILES stage 1 data N1_1204


title: MILES stage 1 data N1_1193


title: MILES stage 1 data N1_1197


title: MILES stage 1 data N1_1194


title: MILES stage 1 data N1_1192


title: MILES stage 1 data N1_1196


title: MILES stage 1 data N1_1195


title: MILES stage 1 data N1_1206


title: MILES stage 1 data N1_1187


title: MILES stage 1 data N1_1186


title: MILES stage 1 data N1_1180


title: MILES stage 1 data N1_1181


title: MILES stage 1 data N1_1201


title: MILES stage 1 data N1_1188


title: MILES stage 1 data N1_1220


title: MILES stage 1 data N1_1190


title: MILES stage 1 data N1_1179


title: MILES stage 1 data N1_1178


title: MILES stage 1 data N1_1191


title: MILES stage 1 data N1_1185


title: MILES stage 1 data N1_1184


title: MILES stage 1 data N1_1183


title: MILES stage 1 data N1_1175


title: MILES stage 1 data N1_1182


title: MILES stage 1 data N1_1177


title: MILES stage 1 data N1_1168


title: MILES stage 1 data N1_1172


title: MILES stage 1 data N1_1176


title: MILES stage 1 data N1_1167


title: MILES stage 1 data N1_1174


title: MILES stage 1 data N1_1173


title: MILES stage 1 data N1_1164


title: MILES stage 1 data N1_1189


title: MILES stage 1 data N1_1166


title: MILES stage 1 data N1_1268


title: MILES stage 1 data N1_1170


title: MILES stage 1 data N1_1171


title: MILES stage 1 data N1_1163


title: MILES stage 1 data N1_1160


title: MILES stage 1 data N1_1156


title: MILES stage 1 data N1_1154


title: MILES stage 1 data N1_1157


title: MILES stage 1 data N1_1149


title: MILES stage 1 data N1_1161


title: MILES stage 1 data N1_1153


title: MILES stage 1 data N1_1155


title: MILES stage 1 data N1_1151


title: MILES stage 1 data N1_1147


title: MILES stage 1 data N1_1150


title: MILES stage 1 data N1_1152


title: MILES stage 1 data N1_1146


title: MILES stage 1 data N1_1141


title: MILES stage 1 data N1_1159


title: MILES stage 1 data N1_1140


title: MILES stage 1 data N1_1158


title: MILES stage 1 data N1_1143


title: MILES stage 1 data N1_1138


title: MILES stage 1 data N1_1145


title: MILES stage 1 data N1_1144


title: MILES stage 1 data N1_1137


title: MILES stage 1 data N1_1134


title: MILES stage 1 data N1_1142


title: MILES stage 1 data N1_1135


title: MILES stage 1 data N1_1133


title: MILES stage 1 data N1_1132


title: MILES stage 1 data N1_1126


title: MILES stage 1 data N1_1127


title: MILES stage 1 data N1_1125


title: MILES stage 1 data N1_1129


title: MILES stage 1 data N1_1130


title: MILES stage 1 data N1_1128


title: MILES stage 1 data N1_1131


title: MILES stage 1 data N1_1123


title: MILES stage 1 data N1_1116


title: MILES stage 1 data N1_1120


title: MILES stage 1 data N1_1118


title: MILES stage 1 data N1_1114


title: MILES stage 1 data N1_1108


title: MILES stage 1 data N1_1106


title: MILES stage 1 data N1_1124


title: MILES stage 1 data N1_1113


title: MILES stage 1 data N1_1102


title: MILES stage 1 data N1_1139


title: MILES stage 1 data N1_1107


title: MILES stage 1 data N1_1110


title: MILES stage 1 data N1_1115


title: MILES stage 1 data N1_1112


title: MILES stage 1 data N1_1103


title: MILES stage 1 data N1_1101


title: MILES stage 1 data N1_1105


title: MILES stage 1 data N1_1119


title: MILES stage 1 data N1_1117


title: MILES stage 1 data N1_1099


title: MILES stage 1 data N1_1100


title: MILES stage 1 data N1_1109


title: MILES stage 1 data N1_1104


title: MILES stage 1 data N1_1098


title: MILES stage 1 data N1_1086


title: MILES stage 1 data N1_1088


title: MILES stage 1 data N1_1083


title: MILES stage 1 data N1_1095


title: MILES stage 1 data N1_1084


title: MILES stage 1 data N1_1087


title: MILES stage 1 data N1_1074


title: MILES stage 1 data N1_1091


title: MILES stage 1 data N1_1093


title: MILES stage 1 data N1_1085


title: MILES stage 1 data N1_1075


title: MILES stage 1 data N1_1094


title: MILES stage 1 data N1_1076


title: MILES stage 1 data N1_1092


title: MILES stage 1 data N1_1072


title: MILES stage 1 data N1_1090


title: MILES stage 1 data N1_1077


title: MILES stage 1 data N1_1079


title: MILES stage 1 data N1_1078


title: MILES stage 1 data N1_1080


title: MILES stage 1 data N1_1071


title: MILES stage 1 data N1_1081


title: MILES stage 1 data N1_1070


title: MILES stage 1 data N1_1096


title: MILES stage 1 data N1_1061


title: MILES stage 1 data N1_1059


title: MILES stage 1 data N1_1068


title: MILES stage 1 data N1_1069


title: MILES stage 1 data N1_1052


title: MILES stage 1 data N1_1065


title: MILES stage 1 data N1_1067


title: MILES stage 1 data N1_1066


title: MILES stage 1 data N1_1054


title: MILES stage 1 data N1_1057


title: MILES stage 1 data N1_1060


title: MILES stage 1 data N1_1058


title: MILES stage 1 data N1_1051


title: MILES stage 1 data N1_1056


title: MILES stage 1 data N1_1047


title: MILES stage 1 data N1_1045


title: MILES stage 1 data N1_1046


title: MILES stage 1 data N1_1043


title: MILES stage 1 data N1_1097


title: MILES stage 1 data N1_1044


title: MILES stage 1 data N1_1048


title: MILES stage 1 data N1_1049


title: MILES stage 1 data N1_1050


title: MILES stage 1 data N1_1073


title: MILES stage 1 data N1_1040


title: MILES stage 1 data N1_1041


title: MILES stage 1 data N1_1039


title: MILES stage 1 data N1_1042


title: MILES stage 1 data N1_1035


title: MILES stage 1 data N1_1031


title: MILES stage 1 data N1_1032


title: MILES stage 1 data N1_1029


title: MILES stage 1 data N1_1022


title: MILES stage 1 data N1_1020


title: MILES stage 1 data N1_1038


title: MILES stage 1 data N1_1024


title: MILES stage 1 data N1_1036


title: MILES stage 1 data N1_1027


title: MILES stage 1 data N1_1017


title: MILES stage 1 data N1_1021


title: MILES stage 1 data N1_1028


title: MILES stage 1 data N1_1034


title: MILES stage 1 data N1_1037


title: MILES stage 1 data N1_1014


title: MILES stage 1 data N1_1062


title: MILES stage 1 data N1_1025


title: MILES stage 1 data N1_1018


title: MILES stage 1 data N1_1023


title: MILES stage 1 data N1_1015


title: MILES stage 1 data N1_1016


title: MILES stage 1 data N1_1019


title: MILES stage 1 data N1_1012


title: MILES stage 1 data N1_1010


title: MILES stage 1 data N1_1006


title: MILES stage 1 data N1_1013


title: MILES stage 1 data N1_1005


title: MILES stage 1 data N1_1008


title: MILES stage 1 data N1_1004


title: MILES stage 1 data N1_1007


title: MILES stage 1 data N1_1009


title: MILES stage 1 data N1_1002


title: MILES stage 1 data N1_0999


title: MILES stage 1 data N1_1001


title: MILES stage 1 data N1_1089


title: MILES stage 1 data N1_0998


title: MILES stage 1 data N1_1055


title: MILES stage 1 data N1_0997


title: MILES stage 1 data N1_1000


title: MILES stage 1 data N1_0996


title: MILES stage 1 data N1_0994


title: MILES stage 1 data N1_0991


title: MILES stage 1 data N1_1003


title: MILES stage 1 data N1_0990


title: MILES stage 1 data N1_0995


title: MILES stage 1 data N1_0987


title: MILES stage 1 data N1_0989


title: MILES stage 1 data N1_0988


title: MILES stage 1 data N1_0983


title: MILES stage 1 data N1_0986


title: MILES stage 1 data N1_0985


title: MILES stage 1 data N1_0982


title: MILES stage 1 data N1_0978


title: MILES stage 1 data N1_0981


title: MILES stage 1 data N1_0974


title: MILES stage 1 data N1_0975


title: MILES stage 1 data N1_0979


title: MILES stage 1 data N1_0969


title: MILES stage 1 data N1_0967


title: MILES stage 1 data N1_1026


title: MILES stage 1 data N1_0973


title: MILES stage 1 data N1_0992


title: MILES stage 1 data N1_0980


title: MILES stage 1 data N1_0971


title: MILES stage 1 data N1_0964


title: MILES stage 1 data N1_0972


title: MILES stage 1 data N1_0976


title: MILES stage 1 data N1_0965


title: MILES stage 1 data N1_0970


title: MILES stage 1 data N1_0963


title: MILES stage 1 data N1_0962


title: MILES stage 1 data N1_0966


title: MILES stage 1 data N1_0968


title: MILES stage 1 data N1_0984


title: MILES stage 1 data N1_0958


title: MILES stage 1 data N1_0960


title: MILES stage 1 data N1_0957


title: MILES stage 1 data N1_0959


title: MILES stage 1 data N1_0951


title: MILES stage 1 data N1_0952


title: MILES stage 1 data N1_0954


title: MILES stage 1 data N1_0949


title: MILES stage 1 data N1_0955


title: MILES stage 1 data N1_0950


title: MILES stage 1 data N1_0946


title: MILES stage 1 data N1_0956


title: MILES stage 1 data N1_0947


title: MILES stage 1 data N1_0943


title: MILES stage 1 data N1_0939


title: MILES stage 1 data N1_0938


title: MILES stage 1 data N1_0937


title: MILES stage 1 data N1_0941


title: MILES stage 1 data N1_0940


title: MILES stage 1 data N1_0942


title: MILES stage 1 data N1_0933


title: MILES stage 1 data N1_0948


title: MILES stage 1 data N1_0961


title: MILES stage 1 data N1_0936


title: MILES stage 1 data N1_0932


title: MILES stage 1 data N1_0934


title: MILES stage 1 data N1_0931


title: MILES stage 1 data N1_0935


title: MILES stage 1 data N1_0977


title: MILES stage 1 data N1_0926


title: MILES stage 1 data N1_0928


title: MILES stage 1 data N1_0929


title: MILES stage 1 data N1_0925


title: MILES stage 1 data N1_0927


title: MILES stage 1 data N1_0923


title: MILES stage 1 data N1_0924


title: MILES stage 1 data N1_0915


title: MILES stage 1 data N1_0920


title: MILES stage 1 data N1_0912


title: MILES stage 1 data N1_0919


title: MILES stage 1 data N1_0921


title: MILES stage 1 data N1_0910


title: MILES stage 1 data N1_0918


title: MILES stage 1 data N1_0911


title: MILES stage 1 data N1_0904


title: MILES stage 1 data N1_0916


title: MILES stage 1 data N1_0930


title: MILES stage 1 data N1_0902


title: MILES stage 1 data N1_0906


title: MILES stage 1 data N1_0914


title: MILES stage 1 data N1_0909


title: MILES stage 1 data N1_0903


title: MILES stage 1 data N1_0907


title: MILES stage 1 data N1_0913


title: MILES stage 1 data N1_0922


title: MILES stage 1 data N1_0900


title: MILES stage 1 data N1_0901


title: MILES stage 1 data N1_0898


title: MILES stage 1 data N1_0953


title: MILES stage 1 data N1_0897


title: MILES stage 1 data N1_0896


title: MILES stage 1 data N1_0894


title: MILES stage 1 data N1_0885

value: AML with t(11q23)/MLL


title: MILES stage 1 data N1_0887


title: MILES stage 1 data N1_0883


title: MILES stage 1 data N1_0886


title: MILES stage 1 data N1_0876


title: MILES stage 1 data N1_0889


title: MILES stage 1 data N1_0878


title: MILES stage 1 data N1_0884


title: MILES stage 1 data N1_0874


title: MILES stage 1 data N1_0881


title: MILES stage 1 data N1_0879


title: MILES stage 1 data N1_0882


title: MILES stage 1 data N1_0891


title: MILES stage 1 data N1_0899


title: MILES stage 1 data N1_0888


title: MILES stage 1 data N1_0875


title: MILES stage 1 data N1_0880


title: MILES stage 1 data N1_0892


title: MILES stage 1 data N1_0895


title: MILES stage 1 data N1_0872


title: MILES stage 1 data N1_0873


title: MILES stage 1 data N1_0871


title: MILES stage 1 data N1_0908


title: MILES stage 1 data N1_0850


title: MILES stage 1 data N1_0852


title: MILES stage 1 data N1_0851


title: MILES stage 1 data N1_0890


title: MILES stage 1 data N1_0847


title: MILES stage 1 data N1_0855


title: MILES stage 1 data N1_0858


title: MILES stage 1 data N1_0846


title: MILES stage 1 data N1_0868


title: MILES stage 1 data N1_0844


title: MILES stage 1 data N1_0857


title: MILES stage 1 data N1_0849


title: MILES stage 1 data N1_0848


title: MILES stage 1 data N1_0859


title: MILES stage 1 data N1_0860


title: MILES stage 1 data N1_0866


title: MILES stage 1 data N1_0863


title: MILES stage 1 data N1_0870


title: MILES stage 1 data N1_0867


title: MILES stage 1 data N1_0843


title: MILES stage 1 data N1_0861


title: MILES stage 1 data N1_0864


title: MILES stage 1 data N1_0841


title: MILES stage 1 data N1_0853


title: MILES stage 1 data N1_0865


title: MILES stage 1 data N1_0845


title: MILES stage 1 data N1_0869


title: MILES stage 1 data N1_0856


title: MILES stage 1 data N1_0838


title: MILES stage 1 data N1_0839


title: MILES stage 1 data N1_0836


title: MILES stage 1 data N1_0840


title: MILES stage 1 data N1_0830


title: MILES stage 1 data N1_0854


title: MILES stage 1 data N1_0817

value: AML with t(15;17)


title: MILES stage 1 data N1_0827


title: MILES stage 1 data N1_0828


title: MILES stage 1 data N1_0818


title: MILES stage 1 data N1_0837


title: MILES stage 1 data N1_0822


title: MILES stage 1 data N1_0824


title: MILES stage 1 data N1_0835


title: MILES stage 1 data N1_0816


title: MILES stage 1 data N1_0832


title: MILES stage 1 data N1_0829


title: MILES stage 1 data N1_0820


title: MILES stage 1 data N1_0833


title: MILES stage 1 data N1_0819


title: MILES stage 1 data N1_0862


title: MILES stage 1 data N1_0825


title: MILES stage 1 data N1_0821


title: MILES stage 1 data N1_0823


title: MILES stage 1 data N1_0831


title: MILES stage 1 data N1_0814


title: MILES stage 1 data N1_0834


title: MILES stage 1 data N1_0815


title: MILES stage 1 data N1_0826


title: MILES stage 1 data N1_0812


title: MILES stage 1 data N1_0808


title: MILES stage 1 data N1_0809


title: MILES stage 1 data N1_0811


title: MILES stage 1 data N1_0807


title: MILES stage 1 data N1_0805


title: MILES stage 1 data N1_0806


title: MILES stage 1 data N1_0813


title: MILES stage 1 data N1_0810


title: MILES stage 1 data N1_0804


title: MILES stage 1 data N1_0791


title: MILES stage 1 data N1_0800


title: MILES stage 1 data N1_0793


title: MILES stage 1 data N1_0794


title: MILES stage 1 data N1_0795


title: MILES stage 1 data N1_0790

value: AML with t(8;21)


title: MILES stage 1 data N1_0784


title: MILES stage 1 data N1_0797


title: MILES stage 1 data N1_0803


title: MILES stage 1 data N1_0802


title: MILES stage 1 data N1_0798


title: MILES stage 1 data N1_0787


title: MILES stage 1 data N1_0783


title: MILES stage 1 data N1_0789


title: MILES stage 1 data N1_0801


title: MILES stage 1 data N1_0788


title: MILES stage 1 data N1_0785


title: MILES stage 1 data N1_0786


title: MILES stage 1 data N1_0799


title: MILES stage 1 data N1_0782


title: MILES stage 1 data N1_0780


title: MILES stage 1 data N1_0774


title: MILES stage 1 data N1_0775


title: MILES stage 1 data N1_0779


title: MILES stage 1 data N1_0777


title: MILES stage 1 data N1_0767


title: MILES stage 1 data N1_0764


title: MILES stage 1 data N1_0773


title: MILES stage 1 data N1_0776


title: MILES stage 1 data N1_0768


title: MILES stage 1 data N1_0770


title: MILES stage 1 data N1_0769


title: MILES stage 1 data N1_0766


title: MILES stage 1 data N1_0772


title: MILES stage 1 data N1_0765


title: MILES stage 1 data N1_0762


title: MILES stage 1 data N1_0752


title: MILES stage 1 data N1_0763


title: MILES stage 1 data N1_0754


title: MILES stage 1 data N1_0771


title: MILES stage 1 data N1_0756


title: MILES stage 1 data N1_0761


title: MILES stage 1 data N1_0757


title: MILES stage 1 data N1_0778


title: MILES stage 1 data N1_0755


title: MILES stage 1 data N1_0759


title: MILES stage 1 data N1_0760


title: MILES stage 1 data N1_0753


title: MILES stage 1 data N1_0751


title: MILES stage 1 data N1_0758


title: N1_2093, non-leukemia, DS

status: Public on Jun 09 2009

description: Microarray classification of myelodysplastic syndrome identifies patients with high risk of AML transformation

source_name: Cardiff

tag: disease state

value: none-of-the-targets


title: N1_2094, non-leukemia, DS

source_name: Berlin


title: N1_2091, non-leukemia, DS

source_name: Munich


title: N1_2083, non-leukemia, DS


title: N1_2089, non-leukemia, DS

source_name: Salamanca


title: N1_2095, non-leukemia, DS


title: N3_0003, AML, DS

value: AML


title: N1_2087, non-leukemia, DS


title: N1_2086, non-leukemia, DS


title: N3_0001, AML, DS


title: N1_2090, non-leukemia, DS


title: N1_2092, non-leukemia, DS


title: N1_2077, non-leukemia, DS


title: N3_0002, AML, DS


title: N1_2096, non-leukemia, DS


title: N1_2084, non-leukemia, DS


title: N1_2081, non-leukemia, DS


title: N1_2082, non-leukemia, DS


title: N1_2088, non-leukemia, DS


title: N1_2085, non-leukemia, DS


title: N1_2080, non-leukemia, DS


title: N1_2079, non-leukemia, DS


title: N1_2071, non-leukemia, DS


title: N1_2070, non-leukemia, DS


title: N1_2072, non-leukemia, DS


title: N1_2069, non-leukemia, DS


title: N1_2074, non-leukemia, DS


title: N1_2076, non-leukemia, DS


title: N1_2078, non-leukemia, DS


title: N1_2073, non-leukemia, DS


title: N1_2067, non-leukemia, DS


title: N1_2068, non-leukemia, DS


title: N1_2046, non-leukemia, DS


title: N1_2062, non-leukemia, DS


title: N1_2061, non-leukemia, DS


title: N1_2044, non-leukemia, DS


title: N1_2064, non-leukemia, DS


title: N1_2047, non-leukemia, DS


title: N1_2053, non-leukemia, DS


title: N1_2048, non-leukemia, DS


title: N1_2063, non-leukemia, DS


title: N1_2057, non-leukemia, DS


title: N1_2056, non-leukemia, DS


title: N1_2045, non-leukemia, DS


title: N1_2040, non-leukemia, DS


title: N1_2052, non-leukemia, DS


title: N1_2041, non-leukemia, DS


title: N1_2035, non-leukemia, DS


title: N1_2051, non-leukemia, DS


title: N1_2049, non-leukemia, DS


title: N1_2043, non-leukemia, DS


title: N1_2038, non-leukemia, DS


title: N1_2042, non-leukemia, DS


title: N1_2036, non-leukemia, DS


title: N1_2060, non-leukemia, DS


title: N1_2066, non-leukemia, DS


title: N1_2039, non-leukemia, DS


title: N1_2050, non-leukemia, DS


title: N1_2037, non-leukemia, DS


title: N1_2030, non-leukemia, DS


title: N1_2027, non-leukemia, DS


title: N1_2033, non-leukemia, DS


title: N1_2025, non-leukemia, DS


title: N1_2028, non-leukemia, DS


title: N1_2024, non-leukemia, DS


title: N1_2029, non-leukemia, DS


title: N1_2026, non-leukemia, DS


title: N1_1279, AML, DS


title: N1_1290, AML, DS


title: N1_1275, AML, DS


title: N1_1269, AML, DS


title: N1_1276, AML, DS


title: N1_1266, AML, DS


title: N1_1281, AML, DS


title: N1_1272, AML, DS


title: N1_1249, AML, DS


title: N1_1264, AML, DS


title: N1_1237, AML, DS


title: N1_1238, AML, DS


title: N1_1255, AML, DS


title: N1_1292, AML, DS


title: N1_1243, AML, DS


title: N1_1260, AML, DS


title: N1_1239, AML, DS


title: N1_1248, AML, DS


title: N1_1265, AML, DS


title: N1_1247, AML, DS


title: N1_1241, AML, DS


title: N1_1231, AML, DS


title: N1_1232, AML, DS


title: N1_1233, AML, DS


title: N1_1224, AML, DS


title: N1_1230, AML, DS


title: N1_1217, AML, DS


title: N1_1218, AML, DS


title: N1_1222, AML, DS


title: N1_1212, AML, DS


title: N1_1227, AML, DS


title: N1_1211, AML, DS


title: N1_1200, AML, DS


title: N1_1199, AML, DS


title: N1_1209, AML, DS


title: N1_1206, AML, DS


title: N1_1215, AML, DS


title: N1_1195, AML, DS


title: N1_1219, AML, DS


title: N1_1192, AML, DS


title: N1_1191, AML, DS


title: N1_1190, AML, DS


title: N1_1182, AML, DS


title: N1_1194, AML, DS


title: N1_1201, AML, DS


title: N1_1189, AML, DS


title: N1_1175, AML, DS


title: N1_1246, AML, DS


title: N1_1178, AML, DS


title: N1_2032, non-leukemia, DS


title: N1_1177, AML, DS


title: N1_1167, AML, DS


title: N1_1166, AML, DS


title: N1_1170, AML, DS


title: N1_1164, AML, DS


title: N1_1171, AML, DS


title: N1_1158, AML, DS


title: N1_1157, AML, DS


title: N1_1168, AML, DS


title: N1_1141, AML, DS


title: N1_1187, AML, DS


title: N1_1140, AML, DS


title: N1_1146, AML, DS


title: N1_1149, AML, DS


title: N1_1138, AML, DS


title: N1_1131, AML, DS


title: N1_1125, AML, DS


title: N1_1143, AML, DS


title: N1_1135, AML, DS


title: N1_1127, AML, DS


title: N1_1120, AML, DS


title: N1_1115, AML, DS


title: N1_1118, AML, DS


title: N1_1109, AML, DS


title: N1_1126, AML, DS


title: N1_1124, AML, DS


title: N1_1104, AML, DS


title: N1_1112, AML, DS


title: N1_1097, AML, DS


title: N1_1110, AML, DS


title: N1_1091, AML, DS


title: N1_1094, AML, DS


title: N1_1089, AML, DS


title: N1_1096, AML, DS


title: N1_1084, AML, DS


title: N1_1083, AML, DS


title: N1_1060, AML, DS


title: N1_1051, AML, DS


title: N1_1056, AML, DS


title: N1_1049, AML, DS


title: N1_1080, AML, DS


title: N1_1213, AML, DS


title: N1_1073, AML, DS


title: N1_1150, AML, DS


title: N1_1081, AML, DS


title: N1_1074, AML, DS


title: N1_1054, AML, DS


title: N1_1039, AML, DS


title: N1_1058, AML, DS


title: N1_1040, AML, DS


title: N1_1062, AML, DS


title: N1_1059, AML, DS


title: N1_1045, AML, DS


title: N1_1044, AML, DS


title: N1_1052, AML, DS


title: N1_1057, AML, DS


title: N1_1041, AML, DS


title: N1_1046, AML, DS


title: N1_1038, AML, DS


title: N1_1066, AML, DS


title: N1_1034, AML, DS


title: N1_1035, AML, DS


title: N1_1025, AML, DS


title: N1_1029, AML, DS


title: N1_1017, AML, DS


title: N1_1023, AML, DS


title: N1_1037, AML, DS


title: N1_1132, AML, DS


title: N1_1087, AML, DS


title: N1_1020, AML, DS


title: N1_1024, AML, DS


title: N1_1031, AML, DS


title: N1_1134, AML, DS


title: N1_1027, AML, DS


title: N1_1123, AML, DS


title: N1_1019, AML, DS


title: N1_1145, AML, DS


title: N1_1014, AML, DS


title: N1_1013, AML, DS


title: N1_1006, AML, DS


title: N1_1004, AML, DS


title: N1_1002, AML, DS


title: N1_1108, AML, DS


title: N1_1012, AML, DS


title: N1_1001, AML, DS


title: N1_1005, AML, DS


title: N1_0996, AML, DS


title: N1_0992, AML, DS


title: N1_0991, AML, DS


title: N1_0988, AML, DS


title: N1_0994, AML, DS


title: N1_0982, AML, DS


title: N1_0985, AML, DS


title: N1_0964, AML, DS


title: N1_0987, AML, DS


title: N1_0972, AML, DS


title: N1_0967, AML, DS


title: N1_0966, AML, DS


title: N1_0984, AML, DS


title: N1_0975, AML, DS


title: N1_0973, AML, DS


title: N1_0963, AML, DS


title: N1_0979, AML, DS


title: N1_0970, AML, DS


title: N1_0977, AML, DS


title: N1_0954, AML, DS


title: N1_0965, AML, DS


title: N1_0943, AML, DS


title: N1_0981, AML, DS


title: N1_0935, AML, DS


title: N1_0950, AML, DS


title: N1_0955, AML, DS


title: N1_0959, AML, DS


title: N1_0960, AML, DS


title: N1_0932, AML, DS


title: N1_0946, AML, DS


title: N1_0953, AML, DS


title: N1_0927, AML, DS


title: N1_0931, AML, DS


title: N1_0923, AML, DS


title: N1_0926, AML, DS


title: N1_0924, AML, DS


title: N1_0919, AML, DS


title: N1_0928, AML, DS


title: N1_0922, AML, DS


title: N1_0895, AML, DS


title: N1_2094, non-leukemia, DQN3


title: N1_0900, AML, DS


title: N1_2093, non-leukemia, DQN3


title: N1_2095, non-leukemia, DQN3


title: N1_0904, AML, DS


title: N1_0920, AML, DS


title: N1_0897, AML, DS


title: N1_0902, AML, DS


title: N1_0912, AML, DS


title: N1_0913, AML, DS


title: N1_0918, AML, DS


title: N1_0914, AML, DS


title: N1_2096, non-leukemia, DQN3


title: N1_1028, AML, DS


title: N3_0003, AML, DQN3


title: N1_2089, non-leukemia, DQN3


title: N1_2092, non-leukemia, DQN3


title: N1_2091, non-leukemia, DQN3


title: N3_0002, AML, DQN3


title: N3_0001, AML, DQN3


title: N1_2090, non-leukemia, DQN3


title: N1_2081, non-leukemia, DQN3


title: N1_2087, non-leukemia, DQN3


title: N1_2088, non-leukemia, DQN3


title: N1_2085, non-leukemia, DQN3


title: N1_2086, non-leukemia, DQN3


title: N1_2082, non-leukemia, DQN3


title: N1_2083, non-leukemia, DQN3


title: N1_2077, non-leukemia, DQN3


title: N1_2078, non-leukemia, DQN3


title: N1_2080, non-leukemia, DQN3


title: N1_2084, non-leukemia, DQN3


title: N1_2073, non-leukemia, DQN3


title: N1_2064, non-leukemia, DQN3


title: N1_2072, non-leukemia, DQN3


title: N1_2057, non-leukemia, DQN3


title: N1_2069, non-leukemia, DQN3


title: N1_2076, non-leukemia, DQN3


title: N1_2060, non-leukemia, DQN3


title: N1_2067, non-leukemia, DQN3


title: N1_2068, non-leukemia, DQN3


title: N1_2079, non-leukemia, DQN3


title: N1_2062, non-leukemia, DQN3


title: N1_2070, non-leukemia, DQN3


title: N1_2061, non-leukemia, DQN3


title: N1_2071, non-leukemia, DQN3


title: N1_2063, non-leukemia, DQN3


title: N1_2074, non-leukemia, DQN3


title: N1_2066, non-leukemia, DQN3


title: N1_2053, non-leukemia, DQN3


title: N1_2056, non-leukemia, DQN3


title: N1_2051, non-leukemia, DQN3


title: N1_2049, non-leukemia, DQN3


title: N1_2052, non-leukemia, DQN3


title: N1_2035, non-leukemia, DQN3


title: N1_2042, non-leukemia, DQN3


title: N1_2029, non-leukemia, DQN3


title: N1_2045, non-leukemia, DQN3


title: N1_2033, non-leukemia, DQN3


title: N1_2038, non-leukemia, DQN3


title: N1_2050, non-leukemia, DQN3


title: N1_2036, non-leukemia, DQN3


title: N1_2030, non-leukemia, DQN3


title: N1_2041, non-leukemia, DQN3


title: N1_2040, non-leukemia, DQN3


title: N1_2025, non-leukemia, DQN3


title: N1_2044, non-leukemia, DQN3


title: N1_2048, non-leukemia, DQN3


title: N1_2043, non-leukemia, DQN3


title: N1_2027, non-leukemia, DQN3


title: N1_2032, non-leukemia, DQN3


title: N1_2024, non-leukemia, DQN3


title: N1_2047, non-leukemia, DQN3


title: N1_2026, non-leukemia, DQN3


title: N1_2039, non-leukemia, DQN3


title: N1_1292, AML, DQN3


title: N1_1290, AML, DQN3


title: N1_2028, non-leukemia, DQN3


title: N1_2037, non-leukemia, DQN3


title: N1_1281, AML, DQN3


title: N1_1275, AML, DQN3


title: N1_1279, AML, DQN3


title: N1_1269, AML, DQN3


title: N1_1265, AML, DQN3


title: N1_1246, AML, DQN3


title: N1_1249, AML, DQN3


title: N1_1272, AML, DQN3


title: N1_1266, AML, DQN3


title: N1_1276, AML, DQN3


title: N1_1230, AML, DQN3


title: N1_1238, AML, DQN3


title: N1_1237, AML, DQN3


title: N1_1255, AML, DQN3


title: N1_1248, AML, DQN3


title: N1_1227, AML, DQN3


title: N1_1233, AML, DQN3


title: N1_1232, AML, DQN3


title: N1_1218, AML, DQN3


title: N1_1222, AML, DQN3


title: N1_1260, AML, DQN3


title: N1_1247, AML, DQN3


title: N1_1243, AML, DQN3


title: N1_1224, AML, DQN3


title: N1_1231, AML, DQN3


title: N1_1239, AML, DQN3


title: N1_1213, AML, DQN3


title: N1_2046, non-leukemia, DQN3


title: N1_1215, AML, DQN3


title: N1_1241, AML, DQN3


title: N1_1211, AML, DQN3


title: N1_1209, AML, DQN3


title: N1_1212, AML, DQN3


title: N1_1201, AML, DQN3


title: N1_1177, AML, DQN3


title: N1_1200, AML, DQN3


title: N1_1190, AML, DQN3


title: N1_1170, AML, DQN3


title: N1_1199, AML, DQN3


title: N1_1168, AML, DQN3


title: N1_1191, AML, DQN3


title: N1_1189, AML, DQN3


title: N1_1164, AML, DQN3


title: N1_1175, AML, DQN3


title: N1_1194, AML, DQN3


title: N1_1195, AML, DQN3


title: N1_1157, AML, DQN3


title: N1_1167, AML, DQN3


title: N1_1166, AML, DQN3


title: N1_1158, AML, DQN3


title: N1_1206, AML, DQN3


title: N1_1171, AML, DQN3


title: N1_1150, AML, DQN3


title: N1_1182, AML, DQN3


title: N1_1149, AML, DQN3


title: N1_1187, AML, DQN3


title: N1_1219, AML, DQN3


title: N1_1217, AML, DQN3


title: N1_1178, AML, DQN3


title: N1_1192, AML, DQN3


title: N1_1141, AML, DQN3


title: N1_1140, AML, DQN3


title: N1_1145, AML, DQN3


title: N1_1143, AML, DQN3


title: N1_1135, AML, DQN3


title: N1_1126, AML, DQN3


title: N1_1132, AML, DQN3


title: N1_1138, AML, DQN3


title: N1_1118, AML, DQN3


title: N1_1131, AML, DQN3


title: N1_1127, AML, DQN3


title: N1_1112, AML, DQN3


title: N1_1124, AML, DQN3


title: N1_1120, AML, DQN3


title: N1_1125, AML, DQN3


title: N1_1134, AML, DQN3


title: N1_1097, AML, DQN3


title: N1_1108, AML, DQN3


title: N1_1123, AML, DQN3


title: N1_1089, AML, DQN3


title: N1_1104, AML, DQN3


title: N1_1087, AML, DQN3


title: N1_1084, AML, DQN3


title: N1_1109, AML, DQN3


title: N1_1091, AML, DQN3


title: N1_1083, AML, DQN3


title: N1_1096, AML, DQN3


title: N1_1115, AML, DQN3


title: N1_1110, AML, DQN3


title: N1_1094, AML, DQN3


title: N1_1081, AML, DQN3


title: N1_1073, AML, DQN3


title: N1_1074, AML, DQN3


title: N1_1066, AML, DQN3


title: N1_1080, AML, DQN3


title: N1_1039, AML, DQN3


title: N1_1059, AML, DQN3


title: N1_1057, AML, DQN3


title: N1_1058, AML, DQN3


title: N1_1044, AML, DQN3


title: N1_1046, AML, DQN3


title: N1_1029, AML, DQN3


title: N1_1054, AML, DQN3


title: N1_1045, AML, DQN3


title: N1_1062, AML, DQN3


title: N1_1028, AML, DQN3


title: N1_1049, AML, DQN3


title: N1_1041, AML, DQN3


title: N1_1038, AML, DQN3


title: N1_1060, AML, DQN3


title: N1_1056, AML, DQN3


title: N1_1034, AML, DQN3


title: N1_1037, AML, DQN3


title: N1_1052, AML, DQN3


title: N1_1035, AML, DQN3


title: N1_1027, AML, DQN3


title: N1_1040, AML, DQN3


title: N1_1031, AML, DQN3


title: N1_1023, AML, DQN3


title: N1_1013, AML, DQN3


title: N1_1025, AML, DQN3


title: N1_1014, AML, DQN3


title: N1_1005, AML, DQN3


title: N1_1004, AML, DQN3


title: N1_0994, AML, DQN3


title: N1_1019, AML, DQN3


title: N1_1006, AML, DQN3


title: N1_1020, AML, DQN3


title: N1_0991, AML, DQN3


title: N1_0979, AML, DQN3


title: N1_0992, AML, DQN3


title: N1_1012, AML, DQN3


title: N1_0984, AML, DQN3


title: N1_0988, AML, DQN3


title: N1_1001, AML, DQN3


title: N1_1017, AML, DQN3


title: N1_0977, AML, DQN3


title: N1_0985, AML, DQN3


title: N1_1024, AML, DQN3


title: N1_0981, AML, DQN3


title: N1_0982, AML, DQN3


title: N1_0973, AML, DQN3


title: N1_1002, AML, DQN3


title: N1_0975, AML, DQN3


title: N1_0987, AML, DQN3


title: N1_1146, AML, DQN3


title: N1_0996, AML, DQN3


title: N1_0972, AML, DQN3


title: N1_0970, AML, DQN3


title: N1_0959, AML, DQN3


title: N1_0967, AML, DQN3


title: N1_1051, AML, DQN3


title: N1_0965, AML, DQN3


title: N1_0955, AML, DQN3


title: N1_0966, AML, DQN3


title: N1_0964, AML, DQN3


title: N1_0950, AML, DQN3


title: N1_0963, AML, DQN3


title: N1_0935, AML, DQN3


title: N1_0928, AML, DQN3


title: N1_0953, AML, DQN3


title: N1_0946, AML, DQN3


title: N1_0960, AML, DQN3


title: N1_0932, AML, DQN3


title: N1_0943, AML, DQN3


title: N1_0922, AML, DQN3


title: N1_0918, AML, DQN3


title: N1_0914, AML, DQN3


title: N1_0919, AML, DQN3


title: N1_0904, AML, DQN3


title: N1_0900, AML, DQN3


title: N1_0895, AML, DQN3


title: N1_0926, AML, DQN3


title: N1_0924, AML, DQN3


title: N1_0923, AML, DQN3


title: N1_0954, AML, DQN3


title: N1_0920, AML, DQN3


title: N1_0913, AML, DQN3


title: N1_0902, AML, DQN3


title: N1_0927, AML, DQN3


title: N1_0931, AML, DQN3


title: AML sample #99

status: Public on Jun 01 2009

city: New York

first: Hans-Ulrich

last: Klein

state: NY

department: Neurology

institute: Columbia University Medical Center

description: de novo AML, NPM1 mutated, other chromosomal aberrations

data_processing: The Robust Multichip Average (RMA) algorithm as implemented in the R package affy (version 1.20.2) was applied to generate probe set level signal intensities. (Irizarry et al., Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003 Apr;4(2):249-64)

label: Biotin

source_name: mononuclear cells after Ficoll purification

extract_protocol: The total RNA was purified with Qiagen RNeasy Mini kits (Qiagen, Hilden, Germany) according to the manufacturer's recommendations.

treatment_protocol: Samples are from untreated patients (de novo AML)

value: 3-positive (mutated)

tag: karyotype

value: other chromosomal aberrations


title: AML sample #102


title: AML sample #98


title: AML sample #101


title: AML sample #100


title: AML sample #76

description: de novo AML, NPM1 mutated, normal karyotype

value: 2-positive (mutated)

value: normal karyotype


title: AML sample #72


title: AML sample #74


title: AML sample #68


title: AML sample #69


title: AML sample #71


title: AML sample #75


title: AML sample #73


title: N1_0912, AML, DQN3


title: N1_0897, AML, DQN3


title: AML sample #61


title: AML sample #59


title: AML sample #58


title: AML sample #57


title: AML sample #65


title: AML sample #63


title: AML sample #64


title: AML sample #62


title: AML sample #52


title: AML sample #66


title: AML sample #60


title: AML sample #55


title: AML sample #53


title: AML sample #56


title: AML sample #54


title: AML sample #48


title: AML sample #49


title: AML sample #50


title: AML sample #47


title: AML sample #51


title: AML sample #24

description: de novo AML, NPM1 wild type, normal karyotype

value: 1-negative (wild type)


title: AML sample #26


title: AML sample #25


title: AML sample #19


title: AML sample #46


title: AML sample #23


title: AML sample #43


title: AML sample #22


title: AML sample #21


title: AML sample #45


title: AML sample #17


title: AML sample #20


title: AML sample #16


title: AML sample #15


title: AML sample #14


title: AML sample #11


title: AML sample #10


title: AML sample #6


title: AML sample #5


title: AML sample #12


title: AML sample #9


title: AML sample #13


title: AML sample #8


title: AML sample #3


title: AML sample #4


title: AML sample #18


title: AML sample #103


title: AML sample #2


title: AML sample #44


title: 3PPS07042002_PC3_cell_spheres

status: Public on Dec 09 2008

city: San Diego

first: John

middle: R

last: Walker

address: 10675 John Jay Hopkins

institute: Genomics Institute of the Novartis Research Foundation

hyb_protocol: standard Affymetrix procedures

scan_protocol: standard Affymetrix procedures

data_processing: gcRMA, scaled to a median intensity of 100

label_protocol: 50 ng total RNA was used in a standard Affymetrix double amplification protocol.

extract_protocol: Total RNA was isolated from cell pellets using the RNeasy kit (Qiagen, Valencia, CA, USA).

treatment_protocol: For flow cytometry, cell were dissociated with Accutase (Innovative Cell Tech Inc., San Diego, CA, USA) and washed 2 times in the staining solution containing Ca2+ and Mg2+-free PBS with 1mM ethylenediaminetetraacetic acid (EDTA), 25mM Hepes (pH 7.0) (Gibco BRL), 0.5% FBS. Cells were stained live in the staining solution containing conjugated anti-CD44 and anti-CD133 antibody (50 min at 4oC). Samples were analyzed on BD LSR II flow cytometer (Beckton Dickinson Immunocytometry Systems, San Jose, CA).  A minimum of (or At least) 500,000 viable cells were measured per sample. For FACS, 2x107 cells were processed for double CD44 and CD133 staining along with appropriate negative controls and single color positive controls. The CD44+/CD133+ and CD44-/CD133- populations were sorted out on a BD FACS Diva cell sorter (Beckton Dickinson Immunocytometry Systems, San Jose, CA).


title: PC3 PURa 1a

status: Public on Jan 22 2009

city: Baltimore

first: Robert

middle: H

last: Getzenberg

state: MD

address: 600 North Wolfe St., 121 Marburg

department: James Buchanan Bradey Urological Institute

institute: The Johns Hopkins School of Medicine

description: Hybridization was performed by the Johns Hopkins Medical Institutions Microarray Core Facility.

hyb_protocol: 16hrs at 45° C with rotation (60rpm) as described by Affymetrix in their GeneChip Expression Analysis Technical Manual, 2004.

scan_protocol: Using Affymetrix’ GeneChip Scanner 3000 7G and default parameters described by the manufacturer in their GeneChip Expression Analysis Technical Manual, 2004.

data_processing: Image analysis using GCOS 1.4, using MAS 5.0 algorithm and manufacturer’s specifications. Global scaling of images to a target intensity of 150.

source_name: Human prostate cancer cell line PC3

label_protocol: One round amplification protocol for total RNA following Affymetrix’ specifications using T7 promoter oligo dT primer for cDNA synthesis, and ENZO IVT kit (www.affymetrix.com, GeneChip Expression Analysis, Technical Manual, 2003).

growth_protocol: DMEM plus 10% fetal bovine serum

extract_protocol: RNeasy Kit (QIAGEN)

treatment_protocol: PC3PURMyc19: PC3 transfected with pcDNA6PURaMyc and selected with blasticidin (monoclonal) (PC3PURaMyc)

tag: the PC3 androgen-independent prostate cancer cell line was transfected with pcDNA6PURaMyc


title: PC3 Mock 1a

treatment_protocol: PC3Mock: PC3 cells transfected with pcDNA6Myc and selected with blasticidin (polyclonal) (PC3Mock)

tag: The PC3 androgen-independent prostate cancer cell line was transfected with pcDNA6Myc


title: CN_AML Patient 238 (U133 Plus 2.0)

status: Public on Aug 29 2008

city: Munich

first: Klaus

last: Metzeler

address: Marchioninistr. 15

department: Department of Internal Medicine III

country: Germany

institute: University of Munich

description: no additional information

hyb_protocol: Sample hybridisation was performed for 16 hours according to standard Affymetrix protocols

scan_protocol: Samples were scanned using an Affymetrix GeneChip scanner

data_processing: Normalization was performed using the variance stabilizing normalization algorithm, and probe set expression values were calculated by the median polish method. Quality control consisted of visual inspection of the array image for artifacts, assessment of RNA degradation plots, and inspection of rank-vs.-residual plots after normalization and probe set  summarization.

source_name: bone marrow mononuclear cells

label_protocol: Biotin labeling of antisense cRNA was performed according to standard Affymetrix protocols

extract_protocol: Mononuclear cells from bone marrow (BM) or peripheral blood (PB) were enriched by Ficoll gradient centrifugation. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany). cDNA preparation and  in vitro transcription were performed according to standard Affymetrix protocols.

treatment_protocol: Pretreatment bone marrow or peripheral blood mononuclear cells from patients with newly diagnosed acute myeloid leukemia (AML) with a normal karyotype

tag: AML normal karyotype (test set) FAB M2; age =70 years; OS = 538 days; status (0=alive/1=dead)


title: PC-3_2

status: Public on Jan 15 2009

city: Iowa City

first: Justin

last: Drake

state: IA

address: 6-509 Bowen Science Building

institute: The University of Iowa

hyb_protocol: According to Affymetrix protocol

scan_protocol: According to Affymetrix protocol

data_processing: MAS 5

label: According to Affymetrix protocol

source_name: PC-3 cell line, replicate 2

label_protocol: According to Affymetrix protocol

growth_protocol: DMEM/F12 with 10% FBS

extract_protocol: We used TRIzol reagent and RNeasy cleanup kit.  We followed both protocols according to manufacturer's instructions. RNA quality was assessed using the Agilent Model 2100 Bioanalyzer (Agilent Technologies).  Five micrograms of total RNA was processed for use on the microarray.

tag: ATCC PC-3 cell line, does express luciferase


title: 3PPS07042001_PC3_cell_monolayer


title: CN_AML Patient 236 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M6; age =56 years; OS = 1304 days; status (0=alive/1=dead)


title: CN_AML Patient 239 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =64 years; OS = 1019 days; status (0=alive/1=dead)


title: AML sample #1


title: CN_AML Patient 241 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =42 years; OS = 241 days; status (0=alive/1=dead)


title: CN_AML Patient 242 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =65 years; OS = 787 days; status (0=alive/1=dead)


title: CN_AML Patient 235 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M6; age =66 years; OS = 398 days; status (0=alive/1=dead)


title: CN_AML Patient 240 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =62 years; OS = 606 days; status (0=alive/1=dead)


title: CN_AML Patient 229 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =77 years; OS = 330 days; status (0=alive/1=dead)


title: CN_AML Patient 234 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =64 years; OS = 74 days; status (0=alive/1=dead)


title: CN_AML Patient 227 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =85 years; OS = 500 days; status (0=alive/1=dead)


title: PC-3_1

source_name: PC-3 cell line, replicate 1

tag: ATCC parental PC-3 cell line, does express luciferase


title: AML sample #67


title: CN_AML Patient 233 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =61 years; OS = 1403 days; status (0=alive/1=dead)


title: CN_AML Patient 230 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =62 years; OS = 1080 days; status (0=alive/1=dead)


title: CN_AML Patient 225 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =62 years; OS = 5 days; status (0=alive/1=dead)


title: CN_AML Patient 228 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =62 years; OS = 342 days; status (0=alive/1=dead)


title: CN_AML Patient 231 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =74 years; OS = 1175 days; status (0=alive/1=dead)


title: CN_AML Patient 221 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =55 years; OS = 1092 days; status (0=alive/1=dead)


title: CN_AML Patient 226 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =59 years; OS = 1 days; status (0=alive/1=dead)


title: CN_AML Patient 222 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =22 years; OS = 271 days; status (0=alive/1=dead)


title: CN_AML Patient 223 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =67 years; OS = 141 days; status (0=alive/1=dead)


title: CN_AML Patient 232 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =52 years; OS = 33 days; status (0=alive/1=dead)


title: CN_AML Patient 218 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =64 years; OS = 1300 days; status (0=alive/1=dead)


title: CN_AML Patient 203 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =66 years; OS = 132 days; status (0=alive/1=dead)


title: CN_AML Patient 213 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =24 years; OS = 1183 days; status (0=alive/1=dead)


title: CN_AML Patient 211 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =69 years; OS = 624 days; status (0=alive/1=dead)


title: CN_AML Patient 208 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =54 years; OS = 1278 days; status (0=alive/1=dead)


title: CN_AML Patient 216 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =79 years; OS = 36 days; status (0=alive/1=dead)


title: CN_AML Patient 202 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =81 years; OS = 14 days; status (0=alive/1=dead)


title: CN_AML Patient 206 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =68 years; OS = 1508 days; status (0=alive/1=dead)


title: CN_AML Patient 205 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =75 years; OS = 259 days; status (0=alive/1=dead)


title: CN_AML Patient 219 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =62 years; OS = 36 days; status (0=alive/1=dead)


title: CN_AML Patient 200 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =72 years; OS = 403 days; status (0=alive/1=dead)


title: CN_AML Patient 197 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =51 years; OS = 1383 days; status (0=alive/1=dead)


title: CN_AML Patient 215 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =40 years; OS = 1173 days; status (0=alive/1=dead)


title: CN_AML Patient 217 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =66 years; OS = 1441 days; status (0=alive/1=dead)


title: CN_AML Patient 212 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =67 years; OS = 210 days; status (0=alive/1=dead)


title: CN_AML Patient 196 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M6; age =36 years; OS = 1133 days; status (0=alive/1=dead)


title: CN_AML Patient 201 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =72 years; OS = 396 days; status (0=alive/1=dead)


title: CN_AML Patient 210 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M0; age =66 years; OS = 979 days; status (0=alive/1=dead)


title: CN_AML Patient 220 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =50 years; OS = 516 days; status (0=alive/1=dead)


title: CN_AML Patient 199 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =61 years; OS = 169 days; status (0=alive/1=dead)


title: CN_AML Patient 192 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =18 years; OS = 1188 days; status (0=alive/1=dead)


title: CN_AML Patient 198 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =50 years; OS = 1518 days; status (0=alive/1=dead)


title: CN_AML Patient 209 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =59 years; OS = 406 days; status (0=alive/1=dead)


title: CN_AML Patient 195 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =47 years; OS = 1168 days; status (0=alive/1=dead)


title: CN_AML Patient 193 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M5; age =75 years; OS = 113 days; status (0=alive/1=dead)


title: CN_AML Patient 194 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =67 years; OS = 1427 days; status (0=alive/1=dead)


title: CN_AML Patient 190 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =71 years; OS = 1374 days; status (0=alive/1=dead)


title: CN_AML Patient 191 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =41 years; OS = 919 days; status (0=alive/1=dead)


title: CN_AML Patient 204 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =62 years; OS = 1056 days; status (0=alive/1=dead)


title: AML sample #7

tag: karyotype


title: CN_AML Patient 188 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M5; age =55 years; OS = 539 days; status (0=alive/1=dead)


title: CN_AML Patient 189 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =72 years; OS = 256 days; status (0=alive/1=dead)


title: CN_AML Patient 182 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =74 years; OS = 52 days; status (0=alive/1=dead)


title: CN_AML Patient 175 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =60 years; OS = 301 days; status (0=alive/1=dead)


title: CN_AML Patient 179 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =55 years; OS = 308 days; status (0=alive/1=dead)


title: CN_AML Patient 178 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M5; age =68 years; OS = 4 days; status (0=alive/1=dead)


title: CN_AML Patient 181 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =55 years; OS = 114 days; status (0=alive/1=dead)


title: CN_AML Patient 186 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =34 years; OS = 1085 days; status (0=alive/1=dead)


title: CN_AML Patient 176 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =69 years; OS = 2 days; status (0=alive/1=dead)


title: CN_AML Patient 172 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =50 years; OS = 1448 days; status (0=alive/1=dead)


title: CN_AML Patient 180 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M5; age =74 years; OS = 937 days; status (0=alive/1=dead)


title: CN_AML Patient 171 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =32 years; OS = 471 days; status (0=alive/1=dead)


title: CN_AML Patient 184 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =63 years; OS = 448 days; status (0=alive/1=dead)


title: CN_AML Patient 177 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M4; age =39 years; OS = 1202 days; status (0=alive/1=dead)


title: CN_AML Patient 168 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =49 years; OS = 96 days; status (0=alive/1=dead)


title: CN_AML Patient 169 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =50 years; OS = 473 days; status (0=alive/1=dead)


title: CN_AML Patient 185 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =63 years; OS = 1405 days; status (0=alive/1=dead)


title: CN_AML Patient 165 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =62 years; OS = 253 days; status (0=alive/1=dead)


title: 943309

status: Public on Feb 12 2008

city: St Louis

first: Jacqueline

last: Payton

state: MO

address: 4320 Forest Park Avenue, Suite 211

institute: Washington University School of Medicine

description: A study that used high-throughput re-sequencing of the kinase domains of 26 Tyrosine kinase genes that are expressed in most acute myeloid leukemia patients. Used genomic DNA from bone marrow (tumor).

hyb_protocol: Chips hybridized according to Manufacturer's protocol

data_processing: Data scaled to array mean of 1500

source_name: Bone marrow specimen from Tumor cells

label_protocol: Chips labeled with biotin according to Manufacturer's protocol

growth_protocol: Bone marrow specimen from Tumor cells

extract_protocol: Trizol reagent standard protocol

tag: fab

tag: Sex

value: M

tag: race

value: W

tag: age on study

tag: cytogenetic change

tag: flt3 d835

tag: flt3 itd

tag: npm1 ins


title: 868231

value: Normal


title: CN_AML Patient 183 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M5; age =59 years; OS = 388 days; status (0=alive/1=dead)


title: 807970


title: 291696

value: F


title: CN_AML Patient 174 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M5; age =55 years; OS = 303 days; status (0=alive/1=dead)


title: 296361


title: CN_AML Patient 166 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M2; age =36 years; OS = 457 days; status (0=alive/1=dead)


title: CN_AML Patient 167 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =45 years; OS = 33 days; status (0=alive/1=dead)


title: CN_AML Patient 164 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =59 years; OS = 21 days; status (0=alive/1=dead)


title: testis b

status: Public on Oct 18 2000

city: Bethesda

first: Brian

last: Oliver

address: 50 South Drive

department: LBG

institute: NIDDK, NIH

description: Testis dissected from adult (12-24 hours post-eclosion) Drosophila melanogaster of the genotype y w67c1.

organism: Drosophila melanogaster

source_name: y w[67c1]/Y testis


title: CN_AML Patient 173 (U133 Plus 2.0)

description: no additional information

tag: AML normal karyotype (test set) FAB M1; age =74 years; OS = 72 days; status (0=alive/1=dead)